tiprankstipranks
Merck & Company (MRK)
NYSE:MRK
US Market
Want to see MRK full AI Analyst Report?

Merck & Company (MRK) Operating Expense Breakdown

15,067 Followers

Operating Expense Breakdown

Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment.
Operating expenses are being driven by episodic, deal‑related and accounting items rather than steady cost inflation: SG&A shows only modest seasonal growth, while R&D spikes reflect large one‑time charges (including the $9B Cidara hit in Q1‑2026 and an expected ~$5.8B R&D impact from the proposed Terns deal). Restructuring and “Other” are similarly lumpy. Management’s note that ex‑one‑offs OpEx rose only ~2% YoY implies non‑GAAP margins are intact, but GAAP EPS will remain volatile around major BD activity.
Date
Research and Development
Selling, General, and Administrative
Other
Restructuring
Jun 30, 2026
$9.74B$2.90B$99.00M$151.00M
Mar 31, 2026
$12.59B$2.70B$138.00M$195.00M
Dec 31, 2025
$3.89B$2.90B$432.00M$213.00M
Sep 30, 2025
$4.23B$2.63B-$238.00M$47.00M
Jun 30, 2025
$4.05B$2.65B-$7.00M$560.00M
Mar 31, 2025
$3.62B$2.55B-$35.00M$69.00M
Dec 31, 2024
$4.58B$2.86B$126.00M$51.00M
Sep 30, 2024
$5.86B$2.73B-$162.00M$56.00M
Jun 30, 2024
$3.50B$2.74B$42.00M$80.00M
Mar 31, 2024
$3.99B$2.48B-$33.00M$123.00M